Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FOR GEMS EGG RETRIEVAL SOLUTION

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company recently obtained the Class III medical device registration certificate for the egg retrieval solution in its Gems series (registration certificate No.: Guo Xie Zhu Jin 20263180183) from the National Medical Products Administration of China ("**NMPA**").

The egg retrieval solution is the core reagent in the first step of IVF procedures, providing essential preconditions for subsequent fertilization, cleavage, and blastocyst development. This product contains gentamicin sulfate to effectively mitigate the risk of sample contamination; it features a HEPES buffer system that can stably maintain pH in non-culture environments, making it suitable for various egg retrieval procedures. With stable performance and a shelf life of up to 52 weeks, the product significantly enhances clinical convenience and practicality.

This approval marks the gradual completion of the full-category and closed-loop layout for the Gems series reagents. Currently, all six products — egg retrieval solution, embryo processing fluid, fertilization medium, cleavage embryo culture medium, blastocyst culture medium and embryo culture medium — have obtained regulatory certification, covering the entire clinical workflow from egg retrieval, gamete processing, fertilization to embryo culture.

The Gems series of assisted reproductive fluids boasts a 30-year history of IVF reagent brand research and development. Led by David Mortimer, a globally renowned authority in the field of embryo culture known as the "Father of Culture Media" at the Sydney IVF Centre in their research and development, these products leverage cutting-edge global research theories on embryo development to create scientific formulations that are more suitable for the developmental patterns of human embryos. The products have undergone 13 years of multi-center clinical validation worldwide, demonstrating long-term stability, safety and efficacy in clinical practice. Furthermore, the entire product line has earned multiple internationally authoritative certifications, including the European conformity (conformité européenne) ("**CE**"), the US Food and Drug Administration ("**FDA**") certification and the Therapeutic Goods Administration of Australia ("**TGA**") certification. Strictly adhering to top-tier international production and quality control standards, their superior product quality has garnered widespread recognition and deep trust from experts in the global reproductive community.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, May 29, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.